Vertex Strikes Novel Reimbursement Deal For Cystic Fibrosis Drugs in Ireland

A novel deal struck by Vertex and the Irish authorities will ensure reimbursement for the company’s cystic fibrosis drugs, Orkambi and Kalydeco, not only for current uses but for newly approved populations – and any new products for the same uses.

Cystic Fibrosis
Vertex has signed a new kind of reimbursement deal for Orkambi and Kalydeco in Ireland

Vertex Pharmaceuticals and the Irish Health Service Executive have struck what the company describes as an “innovative” agreement that provides long-term reimbursement of Vertex Pharmaceuticals’ cystic fibrosis treatment, Orkambi (lumacaftor/ivacaftor) and expands access to the company’s other CF drug, Kalydeco (ivacaftor).

The deal will also cover any future patient populations for which the drugs are approved, as well as any new...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet